Arcus Biosciences Toekomstige groei

Future criteriumcontroles 1/6

Arcus Biosciences zal naar verwachting groeien in winst en omzet met respectievelijk 3.5% en 18.6% per jaar. De winst per aandeel zal naar verwachting groeien met 9.6% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -95.2% zijn.

Belangrijke informatie

3.5%

Groei van de winst

9.6%

Groei van de winst per aandeel

Biotechs winstgroei	27.3%
Inkomstengroei	18.6%
Toekomstig rendement op eigen vermogen	-95.2%
Dekking van analisten	Good
Laatst bijgewerkt	25 Oct 2024

Recente toekomstige groei-updates

Recent updates

Arcus Biosciences: Advancing On Several Fronts

Oct 29

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Sep 23

Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Sep 15

Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

Aug 19

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

May 31

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

May 15

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

May 13

Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

May 10

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Mar 20

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Feb 23

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Feb 22

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Dec 18

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Aug 08

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Jun 15

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

May 05

Arcus Biosciences GAAP EPS of -$0.90 beats by $0.17

Nov 02

Winst- en omzetgroeiprognoses

NYSE:RCUS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	252	-404	-212	-249	9
12/31/2025	218	-377	-445	-360	10
12/31/2024	254	-298	-195	-225	10
6/30/2024	247	-249	-267	-247	N/A
3/31/2024	237	-231	-235	-210	N/A
12/31/2023	117	-307	-330	-306	N/A
9/30/2023	120	-293	-306	-288	N/A
6/30/2023	121	-287	-316	-306	N/A
3/31/2023	119	-279	-326	-314	N/A
12/31/2022	112	-267	426	438	N/A
9/30/2022	433	80	426	446	N/A
6/30/2022	409	67	447	473	N/A
3/31/2022	392	58	439	464	N/A
12/31/2021	383	53	-282	-256	N/A
9/30/2021	38	-278	-263	-244	N/A
6/30/2021	93	-199	14	26	N/A
3/31/2021	85	-168	70	76	N/A
12/31/2020	78	-123	108	111	N/A
9/30/2020	78	-88	150	152	N/A
6/30/2020	15	-112	-93	-92	N/A
3/31/2020	15	-95	-89	-88	N/A
12/31/2019	15	-85	-75	-73	N/A
9/30/2019	7	-80	-73	-71	N/A
6/30/2019	9	-69	-58	-55	N/A
3/31/2019	9	-54	-50	-47	N/A
12/31/2018	8	-50	-47	-43	N/A
9/30/2018	8	-51	-24	-20	N/A
6/30/2018	4	-63	-36	-33	N/A
3/31/2018	3	-59	N/A	-29	N/A
12/31/2017	1	-53	N/A	-25	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat RCUS de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat RCUS de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat RCUS de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van RCUS ( 18.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.8% per jaar).

Hoge groei-inkomsten: De omzet van RCUS ( 18.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat RCUS binnen 3 jaar verliesgevend zal zijn.

Arcus Biosciences Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates decrease by 11%

Price target decreased by 11% to US$34.44

Consensus revenue estimates increase by 52%

Consensus revenue estimates increase by 35%, EPS downgraded

Price target decreased by 7.9% to US$39.70

Price target decreased to US$50.10

Recent updates

Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting

Arcus Biosciences: Advancing On Several Fronts

Arcus Biosciences, Inc. Announces Arcus Biosciences’ HIF-2A Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer

Now 21% undervalued

Arcus Biosciences, Inc. to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium

Arcus Biosciences Looks Compelling Ahead Of Key Clinical Oncology Milestones

Arcus Biosciences (NYSE:RCUS) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Insufficient new directors

Arcus Biosciences, Inc. announced that it expects to receive $250 million in funding

Arcus Biosciences, Inc.'s (NYSE:RCUS) Shares Lagging The Industry But So Is The Business

New major risk - Revenue and earnings growth

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates decrease by 11%

Price target decreased by 11% to US$34.44

Arcus Biosciences, Inc.(NYSE:RCUS) dropped from Russell 2500 Value Index

New major risk - Revenue and earnings growth

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Arcus Biosciences, Inc.'s (NYSE:RCUS) CEO Compensation Is Looking A Bit Stretched At The Moment

Arcus Biosciences: A Preview Of Their Outlook Ahead Of ASCO

Consensus revenue estimates increase by 52%

Party Time: Brokers Just Made Major Increases To Their Arcus Biosciences, Inc. (NYSE:RCUS) Earnings Forecasts

Arcus Biosciences, Inc. Reports Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2024

Here's Why Arcus Biosciences (NYSE:RCUS) Can Manage Its Debt Despite Losing Money

Arcus Biosciences, Inc. Reports Impairment of Long-Lived Assets for the First Quarter Ended March 31, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer recently sold US$241k worth of stock

We Think Arcus Biosciences (NYSE:RCUS) Can Afford To Drive Business Growth

Chief Operating Officer notifies of intention to sell stock

Consensus revenue estimates increase by 35%, EPS downgraded

What Arcus Biosciences, Inc.'s (NYSE:RCUS) 27% Share Price Gain Is Not Telling You

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Arcus Biosciences: Trading At Large Discount To Recent Gilead Investment

Price target decreased by 7.9% to US$39.70

Arcus Biosciences, Inc. Announces Data from A Phase 1B Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naive Metastatic Pancreatic Cancer

Co-Founder notifies of intention to sell stock

Arcus Biosciences, Inc. (NYSE:RCUS) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Co-Founder notifies of intention to sell stock

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

Is Arcus Biosciences (NYSE:RCUS) In A Good Position To Deliver On Growth Plans?

Arcus Biosciences' Oncology Odyssey: The Domvanalimab Journey

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Arcus Biosciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Insufficient new directors

COO & Director notifies of intention to sell stock

Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data

Here's Why We're Not Too Worried About Arcus Biosciences' (NYSE:RCUS) Cash Burn Situation

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcus Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023

New minor risk - Shareholder dilution

Arcus Biosciences, Inc. announced that it expects to receive $19.4526 million in funding from Gilead Sciences, Inc.

COO & Director notifies of intention to sell stock

COO & Director recently sold US$243k worth of stock

COO & Director notifies of intention to sell stock

Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates

Arcus Biosciences, Inc. Provides Updated Results from an Interim Analysis of ARC-7

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences, Inc.'s (NYSE:RCUS) Share Price Could Signal Some Risk

COO & Director recently sold US$147k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Arcus Biosciences, Inc. to Report Q4, 2022 Results on Feb 28, 2023

COO & Director notifies of intention to sell stock

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces Positive Results for the Fourth Interim Analysis of the ARC-7 Study in Patients